Clinical trials
PSMA clinical trials
Below are recruiting psma clinical trials, each written for real people, not researchers. We’re tracking 197 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06219746Recruiting
New imaging scan for high-risk prostate cancer staging
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
Turku, Southwest FinlandAges 18 years+ - NCT06265272Recruiting
PSMA-11 PET/MRI for Liver Cirrhosis
This study uses a special PET/MRI scan with a tracer called PSMA-11 to look at how liver cirrhosis affects the liver. It may help doctors better understand and monitor the disease.
Charlestown, MassachusettsAges 18–99 - NCT06288113RecruitingPhase 2
Re-treatment with 177Lu-PSMA-617 for prostate cancer
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Los Angeles, CaliforniaAges Any age - NCT06353321Recruiting
PSMA-PET imaging for guiding radiation therapy in prostate cancer
This study tests a new way to use a PSMA-PET scan (a special imaging test that finds prostate cancer cells) to guide a type of radiation treatment called BgRT. It is for men with prostate cancer who are already getting a PSMA-PET scan as part of their regular care.
Dallas, TexasAges Any age - NCT06384222RecruitingPhase 2
MRI scan to monitor response to abiraterone before prostate surgery
This trial tests whether a special MRI scan can show how well the drug abiraterone works against high-risk prostate cancer before surgery. If you have high-risk prostate cancer that hasn't spread, you might be able to take abiraterone for a few months and then have a prostatectomy, with the MRI helping your doctor see the drug's effect.
San Francisco, CaliforniaAges 18 years+ - NCT06389097Recruiting
SPECT Scans to Improve Treatment for Advanced Cancer
This study uses special scans (SPECT imaging) to see how radium or lutetium treatments move through your body, helping doctors plan better doses. It's for people with advanced prostate cancer (getting Radium-223) or advanced neuroendocrine tumors (getting 177Lu treatments).
Baltimore, MarylandAges 18–100 - NCT06392295RecruitingPhase 2
PSMA-Guided Radiation for Limited Prostate Cancer Return
This trial tests whether targeted radiation to the lymph nodes in the belly can help men whose prostate cancer has returned in just a few spots after prior radiation. You must have had a PSMA PET/CT scan showing the cancer is limited to pelvic or belly lymph nodes.
Miami, FloridaAges 18 years+ - NCT06398613Recruiting
Using PSMA PET scan before prostate cancer surgery
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
OsloAges 18 years+ - NCT06449781RecruitingPhase 2
177Lu-PSMA after surgery or radiation for high-risk prostate cancer
This study tests a new treatment called 177Lu-PSMA given after standard therapy (surgery or radiation) to see if it can prevent prostate cancer from coming back. It is for patients with high or very high-risk prostate cancer that hasn't spread yet.
GliwiceAges 18 years+ - NCT06484361RecruitingPhase 2
PET/MRI scan for prostate cancer staging before surgery
This trial tests whether a special PET/MRI scan can better see the extent of prostate cancer before surgery. It aims to help doctors plan more precise treatment.
MilanAges 18 years+ - NCT07691697Recruiting
PSMA PET-guided radiation for slowing prostate cancer growth
This trial uses a special scan called PSMA PET to find and treat a small number of cancer spots that are growing while you are on standard treatment. The goal is to give precise radiation to those spots to help keep the rest of the cancer under control.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06906471RecruitingPhase 1/Phase 2
Testing a PSMA dye to improve prostate biopsy
This trial tests a new dye (AS1986NS) that sticks to prostate cancer cells during a biopsy. It aims to help doctors see cancer more clearly. You may be able to join if you are scheduled for a standard prostate biopsy and have no major health issues.
Miami, FloridaAges 18–90 - NCT06496581RecruitingPhase 3
Adding a targeted radiation drug for prostate cancer that hasn't responded well to initial treatment
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
AngersAges 18–80 - NCT06508567Recruiting
MRI-Guided Internal Radiation for Returning Prostate Cancer
This trial tests a new way to use a type of internal radiation (high-dose-rate brachytherapy) guided by MRI to treat prostate cancer that has come back in the same area after previous radiation therapy. It is designed to be more precise and hopefully safer while using the latest PSMA PET scans to make sure the cancer hasn't spread.
Toronto, OntarioAges 18 years+ - NCT06586047RecruitingEarly Phase 1
PSMA PET scan for triple-negative breast cancer
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
Iowa City, IowaAges 18–90 - NCT07690306Enrolling by invitation
AI study to improve prostate cancer diagnosis with MRI and PSMA PET scans
This study is testing whether artificial intelligence can better predict prostate cancer by combining two types of scans (MRI and PSMA PET) along with your medical history, PSA, and biopsy results. If you have already had these scans and a biopsy, your information may help researchers develop a more accurate, non-invasive diagnostic tool.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06657131Recruiting
PSMA PET scan for prostate cancer recurrence
This trial looks at how well a special PET scan (called PSMA PET) can find prostate cancer that has come back after treatment. It uses a radioactive tracer to spot cancer cells. Your doctor may already have ordered this scan as part of your regular care.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT06659926Recruiting
Radium-select study for advanced prostate cancer
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
Amsterdam, North HollandAges 18 years+ - NCT06696326Recruiting
New PET scan for prostate cancer detection
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Xiamen, FujianAges 18–90 - NCT06700057Recruiting
Study of lutetium treatment for prostate cancer
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
BordeauxAges 18 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT06720532Recruiting
Kidney function in men with prostate cancer getting a new targeted radiation therapy
This study looks at how a targeted radiation therapy called 177Lu-PSMA affects kidney function in men with a type of advanced prostate cancer. It aims to understand risk factors to help guide safe treatment.
MunichAges 18 years+ - NCT06769893Recruiting
New PET scan for kidney cancer staging and monitoring
This study tests a new type of PET scan that uses a tracer called 68Ga-RCCB6 to see kidney cancer more clearly. It compares this scan to another PET scan (68Ga-PSMA) to help doctors stage the cancer, check treatment response, and detect any return of the disease.
Xi'an, China, ShaanxiAges 18–75 - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma?
- Yes. Clin2 currently lists 197 recruiting psma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.